Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?

INTRODUCTION: The aim of the study is to investigate whether standard doses of rosiglitazone (4 mg/daily) and ramipril (5 mg/daily) can reverse pre-clinical macrovasculopathy in newly diagnosed never treated type 2 diabetes (T2DM) patients. METHODS: In this randomized, double-blind, placebo-controll...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Rahman, Sayeeda, Ismail, Aziz Al-Shafi, Ismail, Shaiful Bhari, Naing, Nyi Nyi, Rahman, Abdul Rashid Abdul
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove Medical Press 2010
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3262381/
https://ncbi.nlm.nih.gov/pubmed/22291490
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia